{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:37Z","timestamp":1792685977844,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clim.2024.110380","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:28:30Z","timestamp":1729276110000},"page":"110380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells"],"prefix":"10.1016","volume":"269","author":[{"given":"Francesca","family":"Ammoscato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Wafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Skonieczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bestwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Monero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"De Trane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2024.110380_bb0005","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/B978-0-444-52001-2.00029-7","article-title":"\u201cCerebrospinal fluid analysis,\u201d in Multiple Sclerosis and Related Disorders","volume":"122","author":"Giovannoni","year":"2014"},{"issue":"Pt 5","key":"10.1016\/j.clim.2024.110380_bb0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/brain\/113.5.1269","article-title":"A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index. A comparison and diagnostic applications","volume":"113","author":"McLean","year":"1990","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.clim.2024.110380_bb0015","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ana.20890","article-title":"B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation","volume":"59","author":"Meinl","year":"2006","journal-title":"Ann. Neurol."},{"issue":"Pt 4","key":"10.1016\/j.clim.2024.110380_bb0020","first-page":"1089","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.clim.2024.110380_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bpa.12813","article-title":"Extensive subpial cortical demyelination is specific to multiple sclerosis","volume":"30","author":"Junker","year":"2020","journal-title":"Brain Pathol."},{"issue":"4","key":"10.1016\/j.clim.2024.110380_bb0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bpa.12546","article-title":"Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis","volume":"28","author":"Loveless","year":"2018","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.clim.2024.110380_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","article-title":"Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis","volume":"6","author":"Lucchinetti","year":"1996","journal-title":"Brain Pathol."},{"key":"10.1016\/j.clim.2024.110380_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"issue":"S3","key":"10.1016\/j.clim.2024.110380_bb0045","first-page":"1011","article-title":"Cladribine controls multiple sclerosis via memory B cell depletion","volume":"23","author":"Ceronie","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"13","key":"10.1016\/j.clim.2024.110380_bb0050","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/WNL.0000000000000809","article-title":"Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders","volume":"83","author":"Gnanapavan","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clim.2024.110380_bb0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.30.3.240","article-title":"Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate","volume":"30","author":"Tourtellotte","year":"1980","journal-title":"Neurology"},{"issue":"6 PT 2","key":"10.1016\/j.clim.2024.110380_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.26.6_Part_2.59","article-title":"Schemes to eradicate the multiple sclerosis central nervous system immune reaction","volume":"26","author":"Tourtellotte","year":"1976","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clim.2024.110380_bb0065","article-title":"The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis","volume":"9","author":"Lycett","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.clim.2024.110380_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200048","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of Cladribine tablets: a MAGNIFY-MS substudy","volume":"10","author":"Wiendl","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2024.110380_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103931","article-title":"Immunological consequences of cladribine treatment in multiple sclerosis: a real-world study","volume":"64","author":"Rolfes","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2024.110380_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103431","article-title":"Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis","volume":"57","author":"Spiezia","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clim.2024.110380_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clim.2024.110380_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.clim.2024.110380_bb0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clim.2024.110380_bb0100","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"1\u20132","key":"10.1016\/j.clim.2024.110380_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11481-021-09994-3","article-title":"Different susceptibility of T and B cells to cladribine depends on their levels of deoxycytidine kinase activity linked to activation status","volume":"17","author":"Carlini","year":"2022","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"1","key":"10.1016\/j.clim.2024.110380_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.clim.2024.110380_bb0115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2024.110380_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.clim.2024.110380_bb0125","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/acn3.51206","article-title":"Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS","volume":"7","author":"Moser","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.clim.2024.110380_bb0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.clim.2024.110380_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2024.110380_bb0140","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2024.110380_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102983","article-title":"COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab","volume":"52","author":"Buttari","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2024.110380_bb0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study","volume":"27","author":"Rejdak","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8914","key":"10.1016\/j.clim.2024.110380_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"issue":"17 Supplement","key":"10.1016\/j.clim.2024.110380_bb0160","article-title":"Serum NfL in MS patients treated with cladribine: course and predictive value (P1-3.006)","volume":"100","author":"Moser","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2024.110380_bb0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0404.2004.00259.x","article-title":"Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine","volume":"109","author":"Bartosik-Psujek","year":"2004","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.clim.2024.110380_bb0170","first-page":"93","article-title":"Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis","volume":"7","author":"Janiec","year":"2001","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"10.1016\/j.clim.2024.110380_bb0175","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.clim.2024.110380_bb0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624004893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624004893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:13:32Z","timestamp":1732929212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624004893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S1521661624004893"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110380","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.28.24304956","asserted-by":"object"}]},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110380"}}